GP0122
DeviceInjectable gel.
NCT Number: NCT07344584
The primary objective of the study is to evaluate the safety of GP0122 and GP0124 for the correction of lines and wrinkles in the cheek area.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Adult males or non-pregnant, non-breastfeeding adult females.
Inclusion criteria
4-5 apply only to female participants of childbearing potential:
Exclusion criteria
Injectable gel.
Injectable gel.
Time frame: From Day 1 up to last visit (Up to 12 months)
Time frame: From Day 1 up to Day 28
Time frame: Immediately and 30 minutes after each treatment
Time frame: At Months 3, 6, 9 and 12
Time frame: At Months 3, 6, 9 and 12
Contact information is provided by the study sponsor or research team.
Galderma R&D
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07475455
Wrinkle Reduction
Vienna, Austria
View Trial DetailsNCT07551609
Photoaged Facial Skin, Photoaging
Barcelona, Catalonia, Spain
View Trial DetailsNCT06623214
Wrinkle Reduction
San Gabriel, California, United States
View Trial DetailsNCT03285581
Wrinkle Reduction
Brisbane, California, United States
View Trial Details